Bacteremia 2 (BACTS2)

Categories: Genetic diseases

Aliases & Classifications for Bacteremia 2

MalaCards integrated aliases for Bacteremia 2:

Name: Bacteremia 2 57
Bacteremia, Susceptibility to, 2 57 29 6
Bacteremia 57 54 70
Bacteremia, Susceptibility to 57 13
Bacteremia, Susceptibility to, Type 2 39
Bacts2 57


External Ids:

OMIM® 57 614383
UMLS 70 C0004610

Summaries for Bacteremia 2

MalaCards based summary : Bacteremia 2, also known as bacteremia, susceptibility to, 2, is related to neisseria meningitidis infection and toxic shock syndrome. An important gene associated with Bacteremia 2 is CISH (Cytokine Inducible SH2 Containing Protein), and among its related pathways/superpathways is Innate Immune System. The drugs Teicoplanin and Daptomycin have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and liver, and related phenotype is homeostasis/metabolism.

Wikipedia : 73 Bloodstream infections (BSIs), which include bacteremias when the infections are bacterial and fungemias... more...

More information from OMIM: 614383

Related Diseases for Bacteremia 2

Diseases in the Bacteremia 2 family:

Bacteremia 1

Diseases related to Bacteremia 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 897)
# Related Disease Score Top Affiliating Genes
1 neisseria meningitidis infection 31.7 MBL2 LACTB
2 toxic shock syndrome 31.4 LBP CRP BPI
3 urinary tract infection 31.3 CRP CAT
4 cellulitis 31.2 LACTB CRP
5 meningitis 30.9 MBL2 LBP LACTB CRP
6 pneumonia 30.7 SLPI MBL2 LBP LACTB CRP BPI
7 otitis media 30.7 MBL2 LACTB CRP
8 bacterial infectious disease 30.6 MBL2 LBP CRP BPI
9 epiglottitis 30.6 LACTB CRP
10 disease by infectious agent 30.6 MBL2 LBP LACTB CRP
11 gastroenteritis 30.6 LACTB GUSB CRP
12 bacterial meningitis 30.6 MBL2 LACTB CRP
13 pharyngitis 30.5 LACTB CRP
14 bacteriuria 30.5 CRP CAT
15 splenic abscess 30.5 LACTB CRP
16 meningococcemia 30.4 MBL2 BPI
17 mediastinitis 30.4 LACTB CRP
18 lung abscess 30.3 LACTB CRP
19 aspiration pneumonia 30.3 LACTB CRP
20 vasculitis 30.2 MBL2 CRP BPI
21 nocardiosis 30.2 LACTB CRP
22 prosthetic joint infection 30.2 MBL2 CRP
23 bacterial pneumonia 30.2 SLPI LACTB CRP
24 reactive arthritis 30.2 LBP CRP BPI
25 erysipelas 30.1 CRP CAT
26 liver cirrhosis 30.1 SLPI LBP GCG CRP
27 mycobacterium tuberculosis 1 30.1 MBL2 MAPKAPK3 CISH
28 bronchitis 30.0 SLPI LACTB CRP
29 bronchopneumonia 29.9 GUSB CRP
30 mastitis 29.8 SLPI LBP BPI
31 endocarditis 29.7 LBP LACTB CRP
32 choledocholithiasis 29.7 GUSB CRP
33 mesenteric lymphadenitis 29.7 LBP CRP
34 acalculous cholecystitis 29.6 GUSB CRP
35 vaginal discharge 29.5 SLPI CRP
36 pelvic inflammatory disease 29.5 LACTB GUSB CRP
37 lung disease 29.5 SLPI MBL2 CRP BPI
38 bronchiectasis 29.5 SLPI MBL2 CRP BPI
39 volvulus of midgut 29.5 GCG CRP
40 nasopharyngitis 29.4 GCG CRP
41 cystic fibrosis 29.3 SLPI MBL2 LBP LACTB CRP BPI
42 pulmonary disease, chronic obstructive 29.2 SLPI HMGCR CRP
43 apnea, obstructive sleep 29.1 GCG CRP
44 diabetes mellitus 28.3 SLPI MBL2 HMGCR GCG CRP CAT
45 bacteremia 1 11.5
46 flavimonas oryzihabitans infection 11.1
47 trench fever 10.9
48 erysipeloid 10.9
49 bartonellosis 10.9
50 actinobacillosis 10.9

Comorbidity relations with Bacteremia 2 via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Chronic Kidney Disease
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Bacteremia 2:

Diseases related to Bacteremia 2

Symptoms & Phenotypes for Bacteremia 2

Clinical features from OMIM®:

614383 (Updated 20-May-2021)

MGI Mouse Phenotypes related to Bacteremia 2:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.32 CAT CISH CRP GUSB HMGCR LACTB

Drugs & Therapeutics for Bacteremia 2

Drugs for Bacteremia 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Teicoplanin Approved, Investigational Phase 4 61036-62-2
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Tigecycline Approved Phase 4 220620-09-7 5282044
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
carbamide peroxide Approved Phase 4 124-43-6
Hexetidine Approved, Investigational Phase 4 141-94-6
Taurolidine Approved, Investigational Phase 4 19388-87-5
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
Ethambutol Approved Phase 4 74-55-5 3279 14052
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
Vancomycin Approved Phase 4 1404-90-6 441141 14969
Fosfomycin Approved Phase 4 23155-02-4 446987
Oritavancin Approved, Investigational Phase 4 171099-57-3 16129632
Povidone Approved Phase 4 9003-39-8 131751496
Povidone-iodine Approved Phase 4 25655-41-8
Iodine Approved, Investigational Phase 4 7553-56-2 807
Cloxacillin Approved, Investigational, Vet_approved Phase 4 61-72-3 6098
Oxacillin Approved, Investigational Phase 4 66-79-5 6196
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
Nafcillin Approved, Investigational Phase 4 147-52-4, 985-16-0 8982
Octenidine Investigational Phase 4 71251-02-0
Cadexomer iodine Experimental Phase 4 94820-09-4
26 Calcium, Dietary Phase 4
27 Clavulanic Acids Phase 4
28 Penicillin G Benzathine Phase 4
29 Penicillin G Procaine Phase 4
30 Amoxicillin-Potassium Clavulanate Combination Phase 4
31 Pharmaceutical Solutions Phase 4
32 Chelating Agents Phase 4
33 Disinfectants Phase 4
34 Dermatologic Agents Phase 4
35 Clindamycin phosphate Phase 4
36 Clindamycin palmitate Phase 4
37 Neurotransmitter Agents Phase 4
38 Sodium Channel Blockers Phase 4
39 Adrenergic alpha-Agonists Phase 4
40 Anti-Arrhythmia Agents Phase 4
41 Anti-Asthmatic Agents Phase 4
42 Anesthetics, Local Phase 4
43 Adrenergic beta-Agonists Phase 4
44 Diuretics, Potassium Sparing Phase 4
45 Vasoconstrictor Agents Phase 4
46 Adrenergic Agonists Phase 4
47 Mydriatics Phase 4
48 Adrenergic Agents Phase 4
49 Sympathomimetics Phase 4
50 Bronchodilator Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 273)
# Name Status NCT ID Phase Drugs
1 Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia Unknown status NCT03108690 Phase 4 Continuous infusion of beta-lactam antibiotics .
2 An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Unknown status NCT02783404 Phase 4 Amoxicillin;Amoxicillin-Potassium Clavulanate
3 Concentration and Antibiotic Activity in Antibiotic Lock Solutions Unknown status NCT01592032 Phase 4 Vancomycin antimicrobial-lock solution;Teicoplanin antimicrobial-lock solution;Linezolid antimicrobial-lock solution;Daptomycin antimicrobial-lock solution;Tigecycline antimicrobial-lock solution
4 Effects of Ultrasonic Debridement With PVP-iodine Irrigation on Post-treatment Bacteraemia Compared to Ultrasonic Debridement With Water Completed NCT01647347 Phase 4 Supra- and subgingival rinsing with 10% PVP-iodine
5 Influence of Pre-procedural Oral Rinse in the Induced Bacteremia by Periodontal Instrumentation: a Randomized Clinical Trial Completed NCT02215473 Phase 4 Chlorhexidine gluconate mouth rinse
6 Linezolid In The Treatment Of Subjects With Nosocomial Pneumonia Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus Completed NCT00084266 Phase 4 linezolid (Zyvox);vancomycin
7 A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia Completed NCT01701219 Phase 4 Ceftaroline fosamil
8 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
9 A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus. Completed NCT01728376 Phase 4 Daptomycin;Comparator
10 The Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compared With 10% Povidone Iodine in Reducing Blood Culture Contamination in Pediatric Patients Completed NCT01919593 Phase 4 2% chlorhexidine gluconate in 70% alcohol;10%povidone iodine
11 Prophylactic Antimicrobial Catheter Lock in Hemodialysis Patients: A Randomized Controlled Clinical Trial Completed NCT00571259 Phase 4 Heparin 1000U/mL;4% Sodium Citrate with Gentamicin 320 mcg/mL
12 A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia Completed NCT02660346 Phase 4 Daptomycin;Vancomycin;Ceftaroline
13 Bacteraemia Secondary to Tooth Extraction: a Randomized Clinical Trial on Efficacy of Three Different Chlorhexidine Prophylaxis Protocols Completed NCT02150031 Phase 4 0.2% Chlorhexidine;1% Chlorhexidine;1% Chlorhexidine;Lidocaine plus adrenaline
14 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
15 Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen in Adult Critically Ill Patients With Gram Negative Bacilli Bacteremia Completed NCT00609375 Phase 4 cefepime;cefepime
16 An Open-Label Randomized Pharmacokinetic/Pharmacodynamic Study of Mycobutin (Rifabutin) or Rifabutin in Combination With Myambutol (Ethambutol) for Prophylaxis of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts <= 100 Cells/mm3 Completed NCT00002343 Phase 4 Ethambutol hydrochloride;Rifabutin
17 Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia Completed NCT00294502 Phase 4 Gentamycin/citrate, Minocycline/EDTA
18 Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia Completed NCT02972983 Phase 4 Daptomycin
19 Skin Disinfection With Octenidine Dihydrochloride for the Prevention of Catheter-Associated Infections - A Double-Blind, Randomized, Controlled Trial Completed NCT00515151 Phase 4 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol;74% Ethanol with 10% 2-propanol
20 Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation Completed NCT03627884 Phase 4 Sodium Bicarbonate Catheter Lock Solution;Normal Saline Catheter Lock Solution
21 A Randomised Controlled Trial of Taurolidine With Heparin for Prevention of Recurrence of Catheter Related Bacteraemia in Haemodialysis Patients. Completed NCT01243710 Phase 4
22 Evaluation of Antimicrobial Use and Time of Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction (PCR) in Real Time Multiplex to the Conventional Blood Culture for Etiologic Agents Identification. Randomized Clinical Trial. Completed NCT01450358 Phase 4
23 Prospective Trial for Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction Completed NCT02789501 Phase 4
24 Rate of Catheter Colonization and Risk of Bloodstream Infection During Use of a Standard Central Venous Catheter (CVC) in Comparison to a Coated CVC Completed NCT00555282 Phase 4
25 Dressing: Comparison of 3-day and 7-day Catheter Dressing Frequency and Efficacy of Antiseptic Impregnated Dressing in Preventing Catheter-related Infection in ICU Completed NCT00417235 Phase 4
26 Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial Recruiting NCT03671967 Phase 4 Piperacillin/tazobactam;Meropenem
27 Short Course Antibiotic Treatment of Gram-negative Bacteremia: A Multicenter, Randomized, Non-blinded, Non-inferiority Interventional Study Recruiting NCT04291768 Phase 4
28 Efficacy of Seven and Fourteen Days of Antibiotic Treatment in Uncomplicated Staphylococcus Aureus Bacteremia: A Randomized, Non-blinded, Non-inferiority Interventional Study Recruiting NCT03514446 Phase 4 Antibiotic therapy duration for 7 days
29 A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus Aureus Infections in Patients With Opioid Use Disorder Recruiting NCT03761953 Phase 4 Oritavancin Injection
30 Multicenter, Randomised, Open-label Phase III-IV Study to Evaluate the Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With Methicillin-susceptible Staphylococcus Aureus Bacteraemia: SAFO Trial Recruiting NCT03959345 Phase 4 Combination therapy group;Standard therapy group
31 The VANcomycin Cohort Study - Assessing Precise Dosing and Prompt Drug Monitoring to Improve Attainment of Target Concentrations (Part 1) Recruiting NCT04044703 Phase 4 Vancomycin - model-based dosing regimen
32 A Phase 4, Open Label Field Study to Evaluate the Clinical Benefit, Safety, and Pharmacokinetics of Anthim (Obiltoxaximab) When Used in the Treatment of Suspected, Probable, or Confirmed Cases of Inhalational Anthrax Due to B. Anthracis Not yet recruiting NCT03088111 Phase 4
33 A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin® (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis Terminated NCT00638157 Phase 4 daptomycin;daptomycin and gentamicin
34 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4 Synbiotic 2000
35 Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Terminated NCT01734694 Phase 4 Vancomycin;Ceftaroline;Daptomycin;Linezolid
36 Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs) Terminated NCT01287832 Phase 4 Vancomycin;Daptomycin
37 A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment Terminated NCT01104662 Phase 4 Vancomycin;Daptomycin;Semi-Synthetic Penicillin
38 A Randomized Trial of Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal to Reduce Bacteriuria and Catheter-Associated Urinary Tract Infections Terminated NCT03447639 Phase 4 Povidone-iodine irrigation
39 Clinical Phase IV Comparison Trial for 2% Chlorhexidine Skin Asepsis +70% Alcohol Versus Aqueous Chlorhexidine (2%) for the Prevention of Catheter-related Bacteremia in Critical Patients: Preliminary Study Withdrawn NCT03489512 Phase 4 A (Chloraprep);B (Clorhexidine 2%)
40 Lock Con Etanolo Per il Salvataggio di Dispositivi Vascolari a Lungo Termine. Un Trial Clinico Multicentrico Controllato Randomizzato Unknown status NCT01186172 Phase 3 Ethanol-lock therapy;Antibiotic-lock
41 Simplified Selective Digestive Tract Decontamination for the Prevention of ICU Infections in the Setting of High-level Antibiotic Resistance Unknown status NCT01798537 Phase 2, Phase 3 Neomycin Colistin Nystatin Vancomycin
42 A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children Unknown status NCT01619462 Phase 3
43 A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis Completed NCT01223690 Phase 3 Clarithromycin;Dextrose 5%
44 Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed NCT00398411 Phase 3 moxifloxacin;placebo
45 Randomized Multicenter Study to Assess Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin Monotherapy for Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia in Hospitalized Patients Completed NCT01898338 Phase 3 Fosfomycin 2gr/6h iv;Daptomycin 10mg/kg/24h iv
46 A Phase 3, Multicenter, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy In the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to Staph Aureus Completed NCT00093067 Phase 3 daptomycin
47 An Open Label, Multi-center, Randomized, Comparative Phase IIIb Study to Compare Efficacy and Safety of Intravenous (i.v.) Daptomycin With That of Semi-Synthetic Penicillins (SSPs) or Vancomycin in the Treatment of Elderly Patients (Aged ≥ 65 Years) With Complicated Skin and Soft Tissue Infections (cSSTI) Completed NCT01184872 Phase 3 Daptomycin;Vancomycin or Semi-Synthetic Penicillins (SSPs)
48 A Prospective, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of BAY 1192631 in Japanese Patients With MRSA Infections (Skin and Soft Tissue Infection [SSTI] and SSTI-related Bacteremia) Completed NCT01967225 Phase 3 Tedizolid Phosphate (Sivextro, BAY1192631);Linezolid
49 A Randomised Study of Taurolock for the Locking of Tunneled Central Venous Catheters in Children With Malignant Diseases. Completed NCT00735813 Phase 3
50 Short Daily Alcohol Locks for the Prevention of Tunneled Catheter Infection in Patients With Haematological Disease. Randomised Placebo Controlled Trial Completed NCT00122642 Phase 2, Phase 3 placebo-lock

Search NIH Clinical Center for Bacteremia 2

Genetic Tests for Bacteremia 2

Genetic tests related to Bacteremia 2:

# Genetic test Affiliating Genes
1 Bacteremia, Susceptibility to, 2 29 CISH

Anatomical Context for Bacteremia 2

MalaCards organs/tissues related to Bacteremia 2:

Skin, Kidney, Liver, Heart, Lung, Myeloid, Neutrophil

Publications for Bacteremia 2

Articles related to Bacteremia 2:

(show top 50) (show all 121)
# Title Authors PMID Year
CISH and susceptibility to infectious diseases. 6 57
20484391 2010
Bacteremia among children admitted to a rural hospital in Kenya. 57
15635111 2005
Molecular cloning of CISH, chromosome assignment to 3p21.3, and analysis of expression in fetal and adult tissues. 57
9465889 1997
Successful treatment of fulminant Clostridioides difficile infection with emergent fecal microbiota transplantation in a patient with acute myeloid leukemia and prolonged, severe neutropenia. 61
31769569 2020
A Large Mitral Valve Vegetation Not Visualized on Transthoracic Echocardiography: A Case Report. 61
31558692 2019
Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation. 61
30448456 2019
Étude épidémio-clinique des infections à entérobactéries productrices de carbapénémases chez les brûlés. 61
31285728 2019
Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. 61
28278704 2017
Isolation, Detection, and Characterization of Enterotoxigenic Bacteroides fragilis in Clinical Samples. 61
27335618 2016
A psychologist-led educational intervention results in a sustained reduction in neonatal intensive care unit infections. 61
25478550 2014
Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. 61
23439635 2013
Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. 61
21460313 2011
[Diagnostic value of procalcitonin, interleukin 8, interleukin 6, and C-reactive protein for detecting bacteremia and fungemia in cancer patients]. 54
20097454 2010
Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. 54
20423493 2010
[Risk factors for extended espectrum beta-lactamase producer E.coli bacteremia from urinary origin]. 54
20044105 2010
Prognostic value of inflammatory markers (notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis. 54
20146986 2010
An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. 61
20041768 2010
[Post-operative bacteremia caused by multidrug-resistant Aerococcus viridans in a patient with gall bladder cancer]. 54
20455408 2010
USA300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children. 54
19820424 2009
C-reactive protein as a marker of serious bacterial infections in hospitalized febrile infants. 54
19664100 2009
Streptococcus pneumoniae DNA load in blood as a marker of infection in patients with community-acquired pneumonia. 54
19675218 2009
Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia. 54
19949753 2009
Predictors of mortality in patients with bacteremia of unknown source due to extended spectrum beta-lactamase producing Escherichia coli. 54
19622466 2009
Risk index score for bacteremia in febrile neutropenic episodes in children with malignancies. 54
19810131 2009
Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia. 54
19526164 2009
Polymorphic receptors of the innate immune system (MBL/MASP-2 and TLR2/4) and susceptibility to pneumococcal bacteremia in HIV-infected patients: a case-control study. 54
19275590 2009
Risk factors for negative blood cultures in adult medical inpatients--a retrospective analysis. 54
18957115 2008
Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. 54
18661397 2008
C reactive protein (CRP) as a predictor for true bacteremia in children. 54
18443549 2008
Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone. 54
17996417 2008
Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. 54
18056482 2008
[Total white blood cell count, erythrosedimentation rate and C-reactive protein for the detection of serious bacterial infections in 0- to 90-day-old infants with fever without a source]. 54
18341874 2008
New-onset atrial fibrillation in bacteremia is not associated with C-reactive protein, but is an indicator of increased mortality during hospitalization. 54
18434721 2008
Community-acquired thoracic empyema in young adults. 54
17984736 2007
[Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures]. 54
18173077 2007
Dynamics of C-reactive protein and white blood cell count in critically ill patients with nosocomial Gram positive vs. Gram negative bacteremia: a historical cohort study. 54
17868441 2007
Gallstones containing bacteria are biofilms: bacterial slime production and ability to form pigment solids determines infection severity and bacteremia. 54
17546479 2007
Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients. 54
17143875 2007
Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan. 54
17640342 2007
The role of statin therapy in sepsis. 54
17389664 2007
The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. 54
17356388 2007
Association between mannose-binding lectin deficiency and septic shock following acute pyelonephritis due to Escherichia coli. 54
17202308 2007
Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. 54
17202380 2007
Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. 54
16569837 2006
Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. 54
16547275 2006
[Fever in patients of a Service of Internal Medicine: prospective study in 204 cases]. 54
16566652 2006
Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. 54
16323119 2006
Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. 54
15808312 2005
Interleukin-6, interleukin-8, interleukin-10, and C-reactive protein in febrile neutropenia in children with malignant diseases. 54
16761394 2005
Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome. 54
15711657 2004

Variations for Bacteremia 2

ClinVar genetic disease variations for Bacteremia 2:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CISH , MAPKAPK3 NM_001243926.1(MAPKAPK3):c.-436A>T SNV risk factor 7091 rs414171 GRCh37: 3:50649499-50649499
GRCh38: 3:50612068-50612068

Expression for Bacteremia 2

Search GEO for disease gene expression data for Bacteremia 2.

Pathways for Bacteremia 2

Pathways related to Bacteremia 2 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways

GO Terms for Bacteremia 2

Cellular components related to Bacteremia 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 SLPI MBL2 LBP GUSB GCG CRP
2 extracellular space GO:0005615 9.28 SMARCA4 SLPI MBL2 LBP GUSB GCG

Biological processes related to Bacteremia 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.67 SLPI GUSB CAT BPI
2 innate immune response GO:0045087 9.65 SLPI MBL2 LBP CRP BPI
3 response to lipopolysaccharide GO:0032496 9.58 SLPI MAPKAPK3 LBP
4 defense response to Gram-positive bacterium GO:0050830 9.5 MBL2 LBP CRP
5 lipopolysaccharide-mediated signaling pathway GO:0031663 9.46 LBP BPI
6 defense response to bacterium GO:0042742 9.46 SLPI MBL2 LBP BPI
7 interleukin-7-mediated signaling pathway GO:0038111 9.43 SMARCA4 CISH
8 acute-phase response GO:0006953 9.13 MBL2 LBP CRP
9 opsonization GO:0008228 8.8 MBL2 LBP CRP

Molecular functions related to Bacteremia 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 8.96 LBP BPI
2 signaling receptor binding GO:0005102 8.92 MBL2 LBP GUSB GCG

Sources for Bacteremia 2

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....